AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Slightly Bullish +25

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

🏆 AbbVie and adMare BioInnovations announced RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award in Quebec.

🌍 The award recognizes national competition winners to foster innovation within Quebec's life sciences sector.

🎓 RIME Therapeutics will receive one year of laboratory and office space at the adMare Innovation Centre in Montreal.

🧪 The prize includes access to shared equipment, services, and mentorship from AbbVie's scientific and business leaders.

🔬 Founded in 2025, RIME Therapeutics is developing a peptide-based drug discovery platform for inflammation and immunology.

🚀 RIME's Disruptide Platform merges target discovery with simultaneous hit identification to address novel T cell biology.

💰 The award targets early-stage biotech companies aligning with AbbVie's focus areas like immunology, oncology, neuroscience, and aesthetics.

🤝 Michael Mee, CEO of RIME Therapeutics, expressed honor in receiving the award to accelerate their path from novel biology to tractable chemistry.

📈 Matthew Carlyle, President and CEO of adMare BioInnovations, highlighted the partnership's focus on scaling globally competitive Canadian companies.

⚕️ Stéphanie Sauvageau, Head of Medical at AbbVie Canada, emphasized commitment to fostering a thriving life sciences ecosystem across Canada.

🔍 RIME Therapeutics integrates human genetics, perturbation biology, and AI to scan functional drug pocket space.

💼 adMare BioInnovations has helped create 39 companies that attracted $2.5 billion in risk capital and created approximately 1,000 jobs.

🏢 adMare provides over 200,000 square feet of turnkey lab facilities to support Canadian life science scaling.

📅 The announcement was made on April 30, 2026, according to the Globe NewsWire.

📍 RIME Therapeutics is based in Montreal and aims to build a differentiated pipeline of medicines for patients.

Bullish Signals
  • AbbVie has established a strong commitment to fostering innovation in Quebec's life sciences sector by launching the AbbVie Biotech Innovators Award.
  • The award provides RIME Therapeutics, a Montreal-based startup founded in 2025, with a full year of laboratory and office space at the adMare Innovation Centre.
  • RIME Therapeutics will gain access to shared equipment, services, and mentorship from AbbVie's scientific and business leaders, accelerating its drug discovery platform.
  • RIME's Disruptide Platform addresses a persistent challenge in drug discovery by merging target discovery with simultaneous hit identification.
  • The initiative aligns with AbbVie's strategic focus on immunology, oncology, neuroscience, and aesthetics, potentially expanding its therapeutic pipeline.
  • Partner adMare BioInnovations has a proven track record of creating 39 companies that have attracted $2.5 billion in risk capital and achieved a combined value of $5.8 billion.
  • adMare supports early-stage innovation with over 200,000 square feet of turnkey lab facilities, demonstrating robust infrastructure capacity for growth.
Risk Factors
  • No negative aspects or risks were identified in this article; the content focuses entirely on positive achievements, partnerships, and strategic awards.
Full Analysis
AbbVie and adMare BioInnovations have announced that RIME Therapeutics, a Montreal-based start-up founded in 2025, has been selected as the recipient of the AbbVie Biotech Innovators Award for Quebec. Recognized during a national competition, the award highlights AbbVie's dedication to nurturing a robust life sciences ecosystem within the province and supports early-stage biotech companies that align with AbbVie’s therapeutic areas of immunology, oncology, neuroscience, and aesthetics. The award provides RIME Therapeutics with one year of laboratory and office space at the adMare Innovation Centre in Montreal, granting access to shared equipment and services. Furthermore, recipients receive mentorship from AbbVie’s scientific and business leaders to accelerate research advancement. RIME, led by CEO Michael Mee, specializes in a function-first disruptive approach using its Disruptide Platform, which integrates human genetics, perturbation biology, and AI to address inflammation and immunology through protein-protein interaction targets. Matthew Carlyle, President and CEO of adMare BioInnovations, emphasized that the partnership aims to help create globally competitive Canadian companies, while Stéphanie Sauvageau from AbbVie Canada noted the initiative's role in addressing pressing health challenges for Canadians. adMare BioInnovations serves as Canada's life sciences company creation engine, noting its success in helping create 39 companies that have attracted $2.5 billion in risk capital and achieved a combined value of $5.8 billion. The organization provides over 200,000 square feet of turnkey lab facilities and supports scaling through early-stage capital and executive leadership development programs. AbbVie's mission focuses on delivering innovative medicines to solve serious health issues across its key therapeutic areas, including Allergan Aesthetics, striving for a remarkable impact on people's lives today and in the future.